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Abstract
Research  focus:  Identification  of  incidence  of  an  atherogenic  lipoprotein  pheno‐
type  B  in  four  representative  diagnoses  of  cardiovascular  diseases:  a)  arterial
hypertension,  b)  coronary  heart  disease,  c)  lower  extremity  arterial  disease,  d)
ischemic stroke Research methods: A clinical study included 366 patients with a
diagnosis of arterial hypertension (n=107), coronary heart disease (n= 104), lower
extremity arterial disease (n= 100) and ischemic stroke (n= 55). The control group
consisted  of  150  healthy  normotensive  and  normolipemic  volunteers,  all  non-
smokers,  without  signs  of  cardiovascular  disease.  In  all  tested  individuals  (or
subjects)  lipid parameters in serum: cholesterol and triglycerides were analyzed,
using the enzymatic CHOD-PAP method, Roche Diagnostics Germany. Lipopro‐
teins in serum lipoprotein spectrum by Lipoprint LDL system were analyzed and
an atherogenic and a non-atherogenic lipoprotein profile idetified. The Score of the
Anti-Atherogenic Risk (SAAR) was calculated as the ratio between non-atherogen‐
ic and atherogenic lipoproteins.  Results:  More than 80 percent of tested patients
with cardovascular diseases have an atherogenic lipoprotein profile,  with a high
level of strongly atherogenic small dense LDL. The aterogenic profile was found
in  arterial  hypertension  78.5%,  in  coronary  heart  disease  in  81.7%,  in  lower
extremity arterial disease in 80 %, and in patients who survived an ischemic stroke
in 85%. Main conclusion: The atherogenic lipoprotein profile was found to be the
overwhelming  lipoprotein  profile  in  tested  cardiovascular  diseases  A  new
phenomenon- atherogenic normolipidemia - as a risk factor for the development
© 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
of  cardiovascular  disease,  would  be  established  as  a  new  term  used  in  the
diagnostics of dyslipoproteinemias
Keywords: atherogenic lipoproteins, atherogenic lipoprotein profile, small dense
LDL, cardiovascular diseases
1. Introduction
In the last few decades, lipoprotein research has focused on the phenomenon of atherogenic
and non-atherogenic lipoproteins, specifically, atherogenic and non-atherogenic lipoprotein
profiles phenotype A and phenotype B [7, 18, 60] after it was reported that more than 75% of
patients with an acute coronary syndrome or myocardial infarction had normal plasma values
of cholesterol, Low Density Lipoprotein cholesterol (LDL cholesterol) and High Density
Lipoprotein cholesterol (HDL cholesterol) [15 - 17].
Thus, it was necessary to look for other risks factors in plasma, the presence of which in relevant
quantities could cause damage to endothelial cells and resultant endothelial dysfunction [59].
This called into question whether an increased total cholesterol level, or increased LDL-
cholesterol, as a criterion for the degree of atherogenic risk, provided a universal explanation
for the origin of atherogenesis. A reasonable explanation was found in atherogenic lipoprotein
subpopulations, the presence of which in plasma, even in very low concentrations, could
impair the integrity of the vessel wall and lead to endothelial dysfunction with its fatal
consequences [Table 1]: formation of atherothrombotic plaques, acute myocardial infarction,
ischemic stroke, or sudden death [39, 59, 64].
The predominance of atherogenic lipoproteins in plasma is characteristic for the atherogenic
lipoprotein spectrum, phenotype B. When present in plasma in high concentrations, these
lipoproteins contribute to ischemic vascular impairment [6, 8, 57, 60]. The process of degen‐
erative changes in vessels results in the formation of atheromatous vascular plaques. These
later play an important role in the formation of stable or unstable angina (pectoris), and critical
ischemia of peripheral and/or cerebral arteries as well [39,56]. When atherogenic lipoproteins
in plasma are present in small quantities, we obtain a picture of a non-atherogenic lipoprotein
profile, phenotype A.
Various methods have been developed (gradient gel electrophoresis, ultracentrifugation,
magnetic resonance spectroscopy, endothelial models for testing lipoprotein cytotoxicity) to
identify atherogenic lipoproteins [2, 26, 45, 48], but because of technical and financial issues,
long-term analyses and high operating costs, the previously mentioned methods were used
primarily in basic research. Simple analytical procedures for routine distribution were lacking
and the possibility of their implementation in every day laboratory practice remained limited.
An electrophoretic method by which to separate lipoproteins on polyacrylamide gel (PAG)
with the use of Lipoprint LDL System [29, 41] has become a milestone in routine laboratory
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analysis and in diagnosing metabolism disorders of lipoproteins. It enables the analysis of 12
lipoprotein subfractions: VLDL, IDL 1-3, LDL 1-7, and HDL.
1. The Lipoprint LDL system identifies and quantifies
a. Atherogenic lipoproteins (VLDL, IDL1, IDL2, and LDL3-7, so-called small dense
LDL)
b. Non-atherogenic lipoprotein entities (IDL3, HDL)
c. Lipoproteins with uncertain atherogenicity (LDL1, LDL2)
2. And determines
a. The atherogenic vs. non-atherogenic lipoprotein spectrum, phenotype B vs. pheno‐
type A
Atherogenic lipoprotein spectrums are characterized according to the predominance of
atherogenic lipoproteins: very low density (VLDL); intermediate density IDL1 and IDL2; and
by the presence of small dense-low density lipoproteins (sd-LDL). The last represented small
dense LDL are highly atherogenic LDL subfractions that form fractions LDL3-7. As the name
implies, they are smaller than the other types of LDL with a diameter < 26.5 nm (265 Angströms)
and they float within the density range of 1.048–1.065 g/ml, that is, higher than LDL1 and LDL2.
On the separating polyacrylamide gel (PAG) sd-LDL are detected as subtle bands on the anodic
end of the gel, right behind HDL, that migrate to the head of separated lipoproteins.
Small dense LDL are highly atherogenic for [11, 14, 46 ]:
* Low recognition by LDL-receptors (configuration
alterations Apo B ) →
* Enhanced aptitude for oxidation and acetylation →
* Oxide-LDL →  release of pro-inflammatory cytokines→  muscle cell apoptosis
* Oxide-LDL →  release of metalloproteinase→  collagen degradation
* Oxide-LDL
→  enhanced aptitude for trapping by macrophages (scavenger-
receptors)
→  stimulation of foam cell formation
* Easier penetration into the subendothelial space and formation of cholesterol deposits
Table 1. Atherogenicity of small dense LDL
In our studies were analyzed serum lipoprotein spectrums in patients with newly recognized
a) arterial hypertension, b) coronary heart disease, c) lower extremity arterial disease, and d)
in patients who survived a stroke. As mentioned earlier, an analytical method for a quantitative
evaluation of lipoprotein fractions was used, and the incidence of an atherogenic lipoprotein
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spectrum phenotype B (vs. phenotype A) in these four representatives of cardiovascular
diseases was identified. At the same time, a lipoprotein spectrum of a control group of healthy
individuals was examined and tested for the incidence of phenotype B.
2. Arterial hypertension
Arterial hypertension (AH) (Fig. 3) is one of the most serious cardiovascular diseases. More
than 20% of the adult population suffers from this disease. AH is one of the risk factors for
atherosclerosis development of coronary, brain, and peripheral arteries, together with the main
cardinal risk factors, that is, dyslipoproteinemia and tobacco smoking [14,20,38]. Atherogenic
LDL subfractions also play a role in the development of the arterial hypertension [32, 43].
AH is a permanent, long-lasting increase in blood pressure of more than 140/90 mmHg in
people of middle age. In people older than 70 years of age, values higher than 160/95 mmHg
are considered increased. For more extensive guidelines see the Statement of WHO/ISH
(International Society of Hypertension) on the management of hypertension [61].
Dyslipoproteinemia, which frequently accompanies AH and multiplies the risk of athero‐
sclerosis development, can also be considered one of the multiple sources that give rise to
AH [35, 64].
Atherogenic lipoproteins in plasma cause endothelial dysfunction, increase vessel tone, and
support the development of AH, which terminates in organ ischemia [8,50,51,55,57,59].
2.1. Patients
In our study 107 patients with newly diagnosed arterial hypertension were examined.
Repeated blood pressure (BP) examination confirmed an increased blood pressure more than
150 mmHg for systolic and more than 90 mmHg for diastolic blood pressure in all hypertensive
patients. Average systolic blood pressure was 172 ±19 mmHg and average diastolic blood
pressure was 102 ±10 mmHg. The group of hypertensive patients comprised 66 men and 41
women. The average age of the men was 50 ± 17.6 years and the average age of the women
was 51.0 ± 13.4 years.
The control group consisted of 150 healthy normotensive and normolipemic volunteers, all
non-smokers, without signs of cardiovascular disease and without biochemical signs of lipid
metabolism disorders. The average age of the subjects was 21 years, and the control group
involved 50 males and 100 females. Volunteers were recruited from medical students at the
Medical Faculty, who gave written, informed consent, and the study was approved by the
local ethics committee.
2.2. Methods
A blood sample from an antecubital vein was obtained in the morning after a 12-hour fasting
period. Total cholesterol and triglycerides in serum were analyzed from lipid parameters,
Lipoproteins - From Bench to Bedside90
using the enzymatic CHOD-PAP method, Roche Diagnostics Germany. To determine the non-
atherogenic lipoprotein phenotype A and the atherogenic lipoprotein phenotype B, the
Lipoprint LDL System Quantimetrix CA, USA, was used.
The Score of the Anti-Atherogenic Risk (SAAR) was calculated as the ratio between non-
atherogenic and atherogenic lipoproteins in serum [42]. SAAR values over 10.8 represented a
non-atherogenic lipoprotein profile, whereas values under 9.8 represented an atherogenic
lipoprotein profile. The cut off values for a non-atherogenic lipoprotein profile and an
atherogenic lipoprotein profile were calculated from the results of 940 Lipoprint LDL analyses.
Using the Quantimetrix Lipoprint LDL system interpretation, all 940 individuals were
examined (general group of subjects) and tested for the occurrence of atherogenic vs. non-
atherogenic lipoprotein profile and were divided into the two subgroups of subjects with an
LDL profile:
• Indicative of Type A, that is, a non-atherogenic lipoprotein profile phenotype A
• Not indicative of Type A, that is, an atherogenic lipoprotein profile, phenotype B [29]
Statistical evaluation of obtained values was performed with an unpaired student’s t-test. The
level of significance was accepted at p < 0.05.
2.3. Results
In the control group shown in Table 2, along with the individuals with non-atherogenic
normolipidemia, that is, an ideal lipoprotein profile (Fig. 1), a subgroup of normolipidemic
individuals with an atherogenic lipoprotein profile was also identified. This group represented
people with an atherogenic normolipidemia (Fig. 2). These people are clinically healthy,
without clinical or laboratory signs of cardiovascular diseases, but with a positive familial
history for cardiovascular diseases (myocardial infarction) in the parents’ or grandparents’
generation. The triglycerides and LDL3-7 concentrations in the control group with the
atherogenic profile, compared to the individuals with a non-atherogenic lipoprotein profile,
were increased (p < 0.05, respectively, p < 0.0001). The Score of the Anti-Atherogenic Risk
(SAAR) for a non-atherogenic lipoprotein profile is a sensitive indicator by which to differen‐
tiate between an atherogenic and non-atherogenic plasma lipoprotein constellation (non-
atherogenic vs. atherogenic: p < 0.0001).
Chol TAG VLDL LDL1, 2 LDL3-7 LDL HDL Score
(mmol/l±SD)
Control 4.28 1.15 0.60 1.29 0.03 2.31 1.35 37.8
±0.60 ±0.39 ±0.16 ±0.38 ±0.003 ±0.53 ±0.32 ±19.7
(non atherogenic profile n =140)
Control 4.25 1.44 0.68 1.16 0.22 2.24 1.32 6.0
±0.54 ±0.40 ±0.14 ±0.24 ±0.08 ±0.36 ±0.31 ±2.0
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Chol TAG VLDL LDL1, 2 LDL3-7 LDL HDL Score
(mmol/l±SD)
(atherogenic profile n = 10)
Control 4.27 1.17 0.61 1.28 0.04 2.30 1.34 35.8
±0.60 ±0.39 ±0.16 ±0.37 ±0.004 ±0.52 ±0.32 ±18.5
(total number n=150)
Non-atherogenic vs. atherogenic
p<0.05 p< 0.0001 p< 0.0001
Non-atherogenic profile, 93.4 % vs. atherogenic profile, 6.6 %, in control group
Table 2. Serum concentration of lipids, lipoproteins, and SAAR-score in the control group
*Reference ranges derived from 125 serum samples that met the NCEP ATPIII guidelines for desirable lipid status
**LDL-C comprised of the sum of cholesterol in Md bands C through A as well as all the subfractions
Figure 1. Non-atherogenic normolipidemia – Control group, SAAR score: 62.5
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*Reference ranges derived from 125 serum samples that met the NCEP ATPIII guidelines for desirable lipid status
**LDL-C comprised of the sum of cholesterol in Md bands C through A as well as all the subfractions
Figure 2. Atherogenic normolipidemia – atherogenic subgroup of control group atherogenic small dense LDL are
present in LDL 3,4 subfractions SAAR score: 2.7
A non-atherogenic lipoprotein profile in the control group was confirmed in 93.4% healthy
normolipidemic individuals, and an atherogenic lipoprotein profile was found in 6.6%.
Table 3 shows high statistical significance for the analyzed lipid and lipoprotein parameters
between the control group and the group of subjects with arterial hypertension (p < 0.0001,
and for HDL, p <0.03).
In Table 4, 78.5% of patients with arterial hypertension have an atherogenic lipoprotein profile.
There is a highly significantly increased concentration of small dense LDL (subfractions
LDL3-7) in a subgroup of AH-patients, who have an atherogenic profile, compared to the
concentration of small dense LDL in the subgroup of AH-patients with a non-atherogenic
profile, which confirms the predominance of atherogenic lipoproteins in AH-patients and the
creation of atherogenic lipoprotein profile, phenotype B, as well. SAAR in patients with AH
is low, that is, 9.2 (cut off is 10.8), and confirms also the predominance of atherogenic lipopro‐
teins in serum.
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*Reference ranges derived from 125 serum samples that met the NCEP ATPIII guidelines for desirable lipid status
**LDL-C comprised of the sum of cholesterol in Md bands C through A as well as all the subfractions
Figure 3. Arterial hypertension with a borderline hypertriglyceridemia, small dense LDL are present in LDL3, 4 sub‐
fractions, SAAR score: 0.9
Chol TAG VLDL LDL1,2 LDL3-7 LDL HDL Score
(mmol/l SD)
Control 4.27 1.17 0.61 1.28 0.04 2.30 1.34 35.8
±0.60 ±0.39 ±0.16 ±0.37 ±0.004 ±0.52 ±0.32 ±18.5
(total number n=150)
AH 5.19 2.28 0.97 1.54 0.35 3.00 1.25 9.2
±1.10 ±1.07 ±0.34 ±0.55 ±0.25 ±0.91 ±0.34 ± 4.5
(total number n= 107)
Control vs. AH
p<0.0001 p< 0.03 p< 0.0001
Table 3. Serum concentration of lipids, lipoproteins, and SAAR-score in AH patients vs.
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Chol TAG VLDL LDL1,2 LDL3-7 LDL HDL Score
(mmol/l SD)
AH 5.32 1.56 0.84 1.78 0.08 3.02 1.49 24.2
±0.98 ±0.55 ±0.31 ±0.44 ±0.04 ±0.71 ±0.34 ±13.6
(non-atherogenic profile n= 23)
AH 5.15 2.48 1.01 1.47 0.42 2.99 1.18 5.1
±1.14 ±1.34 ±0.35 ±0.58 ±0.31 ±0.96 ±0.34 ± 2.0
(atherogenic profile n= 84)
AH 5.19 2.28 0.97 1.54 0.35 3.00 1.25 9.2
±1.10 ±1.07 ±0.34 ±0.55 ±0.25 ±0.91 ±0.34 ± 4.5
(total number n=107)
Non-atherogenic vs. atherogenic
n.s. p<0.002 p<0.05 p<0.02 p< 0.0001 n.s. p< 0.001 p< 0.0001
Atherogenic 78.5% vs. non-atherogenic 21.5% – arterial hypertension
Table 4. Serum concentration of lipids, lipoproteins, and SAAR-score in patients with arterial hypertension
3. Coronary heart disease
Coronary heart disease (CHD) (Fig. 4) is a common manifestation of cardiovascular diseases
and is frequently associated with lipid and lipoprotein metabolism disorders. Hypercholes‐
terolemia and hypertriglyceridemia, as well as combined hyperlipoproteinemia are regular
features that accompany CHD [22,50,51]. Pathophysiologically, the cause of myocardial
ischemia is a disproportion, or imbalance, between myocardial oxygen supply and oxygen
demand. Ischemia in stable angina is generally due to fixed atheromatous stenosis of one or
more coronary arteries as a consequence of impaired lipoprotein metabolism and the formation
of lipid atheromas in the coronary arteries [5, 33, 34,49].
However, clinically, stable angina is not the only form of manifestation of coronary heart
disease. Stable angina, as an ischemia due to fixed atheromatous stenosis, can turn into a
myocardial ischemia due to plaque rupture with thrombosis and spasm of the artery (instable
angina). In addition, myocardial necrosis (myocardial infarction), caused by acute occlusion
of a coronary artery (due to plaque rupture and thrombosis), can have fatal consequences for
disabled persons. It can be supposed that the modified forms of lipoproteins can play an
important role in any form of clinical manifestation of coronary heart disease. Recently, clinical
studies reported that the atherogenic lipoprotein populations (lipoprotein subfractions),
presented in the plasma lipoprotein spectrum in high concentrations, play an important role
in the development of atherosclerotic changes in the arterial wall [14, 38, 39].
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We distinguish facultative atherogenic very low density lipoproteins, VLDL, and their
remnants, intermediate density lipoproteins, IDL, low density lipoproteins, LDL (considered
a lipoprotein family with high atherogenicity), and high density lipoproteins, HDL. Modified
lipoprotein entities in all these lipoprotein families can play a role in the formation of athero‐
genic lipoproteins, which accelerate the atherogenesis in the artery walls, including in the
coronary arteries.
In our study, we focused on the determination of the incidence of an atherogenic lipoprotein
phenotype in patients with coronary heart disease – in stable angina patients.
3.1. Patients
In our study, 104 patients with newly diagnosed coronary heart disease were examined. The
diagnosis of CHD (stable angina pectoris grade I or II) was confirmed by medical examination,
laboratory results, resting ECG, results of echocardiography, and duplex ultrasound of the
carotid arteries.
*Reference ranges derived from 125 serum samples that met the NCEP ATPIII guidelines for desirable lipid status
**LDL-C comprised of the sum of cholesterol in Md bands C through A as well as all the subfractions
Figure 4. Coronary heart disease combined with an atherogenic hypercholesterolemia. High concentration of athero‐
genic small dense LDL in LDL 3,4 subfractions SAAR score: 5.1
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3.2. Methods
See methods published in the section “Arterial hypertension (AH).”
3.3. Results
The results of lipid parameters presented in Table 5 confirm a highly significant increased
concentration of analyzed lipid and lipoprotein parameters (p<0.0001) in CHD-patients,
compared to control values and a low value of the SAAR. These low values (< 10.8) are regularly
found in atherogenic lipoprotein phenotype B.
Chol TAG VLDL LDL1,2 LDL3-7 LDL HDL Score
(mmol/l SD)
Control 4.27 1.17 0.61 1.28 0.04 2.30 1.34 35.8
±0.60 ±0.39 ±0.16 ±0.37 ±0.004 ±0.52 ±0.32 ±18.5
(total number n=150)
CHD 5.25 2.41 0.99 1.52 0.41 3.06 1.18 5.6
±1.15 ±1.72 ±0.43 ±0.47 ±0.29 ±0.85 ±0.29 ± 3.8
(total number n= 104)
Control vs. CHD
p<0.0001
Table 5. Serum concentration of lipids, lipoproteins, and SAAR-score in CHD patients vs. control group
Chol TAG VLDL LDL1,2 LDL3-7 LDL HDL Score
(mmol/l±SD)
CHD 5.26 1.44 0.82 1.73 0.13 3.11 1.29 12.7
±0.99 ±0.50 ±0.27 ±0.49 ±0.06 ±0.80 ±0.31 ±5.1
(non-atherogenic profile = 19)
CHD 5.25 2.63 1.02 1.47 0.48 3.05 1.16 4.0
±1.19 ±2.03 ±0.47 ±0.46 ±0.35 ±0.86 ±0.28 ±3.5
(atherogenic profile n= 85)
CHD 5.25 2.41 0.99 1.52 0.41 3.06 1.18 5.6
±1.15 ±1.72 ±0.43 ±0.47 ±0.29 ±0.85 ±0.29 ±3.8
(total number n=104)
Non-atherogenic vs. atherogenic profile
p<0.01 p<0.05 p< 0.0001 n.s. p< 0.0001
Note: In the column without published p values, the differences in the evaluated parameter were not significant (n.s.)
Atherogenic 81.7% vs. non-atherogenic 18.3%, in coronary heart disease
Table 6. Serum concentration of lipids, lipoproteins, and SAAR-score in coronary heart disease
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In Table 6, an atherogenic lipoprotein phenotype B is present in 81.7% of patients with CHD.
An increased concentration of small dense LDL (LDL3-7) in the CHD-patient subgroup with
an atherogenic lipoprotein profile, compared to the results of the CHD-patient subgroup with
a non-atherogenic lipoprotein profile (p<0.0001), confirms a predominance of atherogenic
lipoproteins in the serum of patients with CHD.
4. Lower extremity arterial disease
Lower extremity arterial disease (LEAD) (Fig. 5) is a common atherogenic disease of the
cardiovascular system. Patients with LEAD exhibit normal to high atherogenic dyslipopro‐
teinemia [8, 31, 50 -52, 62].
*Reference ranges derived from 125 serum samples that met the NCEP ATPIII guidelines for desirable lipid status
**LDL-C comprised of the sum of cholesterol in Md bands C through A as well as all the subfractions
Figure 5. Lower extremity arterial disease with combined atherogenic hyperlipoproteinemia with high concentration
of atherogenic small dense LDL (LDL3,4 subfractions) SAAR score: 1.5
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Almost all lower extremity arterial disease is due to atherosclerotic changes in artery vessels,
and the pathology of LEAD is also similar to coronary heart disease. The most important risk
factor for the development and progression of atherosclerotic LEAD are tobacco smoking,
arterial hypertension, and hyperlipidemia. Other risk factors include diabetes mellitus, low
physical activity, and a diet rich in lipids and carbohydrates. However, dyslipidemia plays an
important role. Increased lipid levels of cholesterol and triglycerides are generally accepted as
important risk factors for the development of atherosclerosis [14,25, 47].
In the last few decades, there has been much discussion about which atherogenic lipoproteins
participate in the formation of the atherogenic lipoprotein profile, phenotype B. Atherogenic
lipoproteins in relevant concentration in the blood serum are responsible for the acceleration
of the development of atherogenic cardiovascular diseases, including the development of
LEAD. The LDL subpopulations of small dense LDL are considered to be strongly atherogenic
lipoprotein entities in the plasma/serum lipoprotein spectrum [38,59] with consequent
acceleration of endothelial dysfunction and formation of the atheromatous subendothelial
plaques in the arteries [21]. In the present study, we have focused on determining the incidence
of an atherogenic lipoprotein phenotype, along with determining the role of atherogenic serum
lipoproteins, in patients with lower extremity arterial disease.
4.1. Patients
In the clinical study, 100 patients with newly diagnosed lower extremity arterial disease were
examined. The study included 55 males and 45 females: the average age of males was 56.0
years ±11 years and the average age of females 52.5 years ± 14 years. The patients had C2a
degree, according to the Claudication classification: [proximal type (AP), the first degree (P1)
with dyslipidemia]. Patients were ex-smokers.
LEAD was diagnosed according to the history of disease, intermittent claudication, the medical
examination, including physical examination (Ratschow’s test in the modification according
to Linhart, see the Angiological Section of Slovak Medical Chamber) [23, 24, 27, 28] and
examination of the ankle-brachial (pressure) index (ABPI) [40, 55, 57].
4.2. Methods
See methods published earlier in the section “Arterial hypertension (AH).”
4.3. Results
Results of lipid parameters presented in Table 7 confirm the highly significant increased
concentration of analyzed lipid and lipoprotein parameters in LEAD-patients (p<0.0001),
compared to control values. The low values of the SAAR, which is generally low (< 10.8) in the
atherogenic lipoprotein phenotype, also confirms the atherogenic lipoprotein constellation in
the serum of LEAD-patients.
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Chol TAG VLDL LDL1,2 LDL3-7 LDL HDL Score
(mmol/l SD)
Control 4.27 1.17 0.61 1.28 0.04 2.30 1.34 35.8
±0.60 ±0.39 ±0.16 ±0.37 ±0.004 ±0.52 ±0.32 ±18.5
(total number n=150)
LEAD 5.29 2.21 0.96 1.58 0.39 3.11 1.21 7.2
±1.21 ±1.05 ±0.37 ±0.51 ±0.28 ±0.96 ±0.31 ± 4.5
(total number n= 100)
Control vs. LEAD
«...............................................p<0.0001.................................»
Table 7. Serum concentration of lipids, lipoproteins, and SAAR-score in LEAD-patients vs. control group
Chol TAG VLDL LDL1,2 LDL3-7 LDL HDL Score
(mmol/l±SD)
LEAD 5.37 1.81 0.86 1.82 0.10 3.18 1.33 17.4
±0.95 ±0.51 ±0.26 ±0.54 ±0.03 ±0.82 ±0.29 ± 6.5
(non-atherogenic profile n= 20)
LEAD 5.28 2.31 0.98 1.52 0.46 3.09 1.18 4.6
±1.28 ±1.18 ±0.39 ±0.50 ±0.34 ±0.99 ±0.32 ± 4.0
(atherogenic profile n= 80)
LEAD 5.29 2.21 0.96 1.58 0.39 3.11 1.21 7.2
±1.21 ±1.05 ±0.37 ±0.51 ±0.28 ±0.96 ±0.31 ± 4.5
(total number n=100)
Non-atherogenic vs. atherogenic
p<0.01 p<0.001 p<0.05 p< 0.0001 p< 0.0001
Atherogenic 80% vs. non-atherogenic 20% in lower extremity arterial disease
Table 8. Serum concentration of lipids, lipoproteins, and SAAR-score in lower extremity arterial disease
In 80% of patients (Table 8), LEAD was associated with an atherogenic lipoprotein phenotype.
An increased concentration of small dense LDL (LDL3-7 subgroups) in the LEAD-patients with
an atherogenic lipoprotein profile, compared to the results from the LEAD-patients with a non-
atherogenic lipoprotein profile (p<0.0001), confirms the predominance of atherogenic lipo‐
proteins in serum in the subgroup of patients with an atherogenic lipoprotein profile.
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5. Stroke
Stroke (Fig. 6) is the leading cause of mortality and of long-term morbidity in the populations
of developed industrialized countries in the world. The atherogenic serum lipoproteins in high
concentrations create an atherogenic lipoprotein profile, which plays a key role in the acute
onset of cardiovascular and cerebrovascular events, that is, stroke [54,55]. Cerebral stroke
attack remains a frequent medical problem and is the third most frequent cause of mortality
all over the world. It represents a heterogeneous group of diseases with more than 150 known
causes. In 25–39% of strokes, the cause leading to the acute cerebrovascular event cannot
usually be definitively explained [4].
Figure 6. Patient survived an ischemic stroke with combined atherogenic hyperlipoproteinemia high concentration of
VLDL, VLDL remnants and atherogenic small dense LDL, i.e. LDL 3, 4 subfractions. SAAR score: 2.4*Reference ranges
derived from 125 serum samples that met the NCEP ATPIII guidelines for desirable lipid status**LDL-C comprised of
the sum of cholesterol in Md bands C through A as well as all the subfractions
Dyslipidemia represents a risk factor for the development of cardiovascular disease, and thus
dyslipidemia has been classified as an atherogenic phenomenon. The goal of the treatment of
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hyperlipoproteinemia, that is, of dyslipidemia, is to reduce the lipid concentration in serum
to established target values of lipids (cholesterol and triglycerides), but the primary goal is to
reduce the atherogenic potential of serum lipids [9, 21, 53]. Dyslipoproteinemia is also the key
phenomenon in the pathogenesis of the onset of atherosclerotic alterations in brain vessels [64].
Accompanied by high cholesterol levels – a classic risk factor for the development of cardio‐
vascular diseases – an increased concentration of triglycerides in the blood serum can also play
an important role in atherogenesis [3,58].
There are several studies that have provided evidence for the relation between carotid artery
stenosis and an ischemic cerebral event [55]. However, the causal inter-relation between
dyslipidemia and stroke has not been explained sufficiently [3, 4, 63]. Relapsing ischemic
strokes account for one-fourth of all strokes in a year and are a strong evidence for a failure of
secondary prevention [10]. This hard reality leads rightly so to the idea of optimal stroke
prevention through the selection of individuals, who are at risk of stroke [13]. The aim of this
pilot study was to identify the atherogenic lipoproteins and determine the lipoprotein profile
in subjects who had suffered an ischemic cerebrovascular event, that is, stroke.
5.1. Patients
The study included 55 patients, 23 men, with an average age of 64 years ± 13 years, and 32
women, average age 74 years ± 13 years, who survived an ischemic cerebrovascular event, that
is, a large-artery atherosclerosis subtype of stroke. To determine the subtype of ischemic stroke,
the original TOAST (Trial of ORG 10172 in Acute Stroke Treatment) [1] criteria were used. The
diagnosis of subtype was based on the risk factor profiles, clinical features, and results of
diagnostic tests, including CT scan/MRI, vascular imaging (carotid duplex, transcranial
Doppler), EEG – electroencephalography, echocardiography (transesophageal/ transthoracic),
assessment of prothrombotic syndromes [1,30], activated partial thromboplastin time (aPTT),
and international normalized ratio (INR).
5.2. Methods
See methods published in the section “Arterial hypertension (AH).”
A blood sample from the antecubital vein was obtained throughout the 24 hours after the onset
of cerebrovascular event.
5.3. Results
The results of lipid parameters presented in Table 9 confirm a highly significantly increased
concentration of analyzed lipid and lipoprotein parameters (p<0.0001) in people who survive
a stroke, compared to control values, and also a low value on the SAAR, which is generally
low (< 10.8) in an atherogenic lipoprotein phenotype.
In Table 10, an atherogenic lipoprotein phenotype was identified in 85.5 % of the patients who
survive a cerebral ischemic stroke. The increased concentration of small dense LDL (LDL3-7
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subgroups) in the atherogenic lipoprotein profile of patients with stroke, compared to the
results in a non-atherogenic lipoprotein profile, is mild, but significant (p<0.05). The difference
in the SAAR between the two subgroups was highly significant (p<0.0001), which also
confirmed the overwhelming atherogenic lipoprotein constellation in patients who survived
a stroke. The concentration of LDL1 was significantly higher in the subgroup of stroke-patients
with a non-atherogenic lipoprotein profile (p<0.0001), however, the difference in the LDL2
lipoprotein subfraction was not significant.
Chol TAG VLDL LDL1,2 LDL3-7 LDL HDL Score
(mmol/l SD)
Control 4.27 1.17 0.61 1.28 0.04 2.30 1.34 35.8
±0.60 ±0.39 ±0.16 ±0.37 ±0.004 ±0.52 ±0.32 ±18.5
(total number n=150)
Stroke 5.19 2.21 1.08 1.56 0.29 2.91 1.09 6.40
±1.10 ±0.91 ±0.34 ±0.57 ±0.24 ±0.82 ±0.32 ±4.22
(total number n= 55
Control vs. stroke
«........................................p<0.0001..........................................»
Table 9. Serum concentration of lipids, lipoproteins, and SAAR-score in stroke patients vs. control group.
Chol TAG VLDL LDL1,2 LDL3-7 LDL HDL Score LDL1 LDL2
(mmol/l±SD)
Stroke 5.54 1.70 0.93 2.19 0.14 3.30 1.31 13.74 1.22 0.92
±1.30 ±0.44 ±0.14 ±0.86 ±0.07 ±1.01 ±0.35 ±1.36 ±0.45 ±0.44
(non-atherogenic profile n= 8)
Stroke 5.14 2.29 1.11 1.48 0.31 2.86 1.06 5.33 0.72 0.76
±1.11 ±0.94 ±0.37 ±0.41 ±0.23 ±0.72 ±0.29 ±3.32 ±0.26 ±0.26
(atherogenic profile n = 47)
Stroke 5.19 2.21 1.08 1.56 0.29 2.91 1.09 6.40 0.78 0.78
±1.06 ±0.91 ±0.35 ±0.53 ±0.23 ±0.77 ±0.31 ± 4.22 ±0.33 ±0.28
(total number n= 55)
Non-atherogenic vs. atherogenic
n.s. n.s. n.s. p<0.002 p<0.05 n.s. n.s. p< 0.0001 n.s. p< 0.0001
Atherogenic 85.5 % vs. non-atherogenic 14.5 % in stroke patients.
Table 10. Serum concentration of lipids, lipoproteins, and SAAR-score in patients with stroke.




In the last few decades, lipoprotein research has focused on the phenomenon of atherogen‐
ic and non-atherogenic lipoproteins, and on the phenotype A vs. phenotype B characteriza‐
tion, as a consequence of the published evidence that the majority of the patients with an
acute  coronary  syndrome  or  patients  who  survive  a  myocardial  infarction  had  normal
plasma values of cholesterol, LDL-cholesterol, and HDL-cholesterol [15-17]. A reasonable
explanation for this  fact  was to posit  a  new, active atherogenic substance in plasma, an
atherogenic  lipoprotein  subfraction,  the  presence  of  which in  plasma,  even in  very  low
concentrations,  could  impair  the  integrity  of  the  vessel  wall  and  lead  to  endothelial
dysfunction with its fatal consequences. Several clinical studies reported observations that
in  the plasma of  patients  with coronary heart  disease  there  are  subfractions of  lipopro‐
teins,  which  could  play  a  crucial  role  in  atherodegenerative  processes  and  form  the
atherothrombotic  plaques  [5,  33,  34,  37,  39,49].  The  Quebec  Cardiovascular  Study,  a
prospective study of 2,103 men [33,34] concluded that “ a significant proportion of the risk
for  heart  disease  associated  with  small,  dense  LDL  particles  may  be  independent  of
variations in plasma lipid concentrations. Small  LDL particles and elevated apo B levels
were found to be the most predictive indications for ischemic heart disease ”.
For this reason, patients who were suffering from cardiovascular diseases were examined in
order to quantify the atherogenic lipoproteins in serum and to determine the incidence of an
atherogenic lipoprotein profile in patients who had a diagnosis of cardiovascular diseases.
The clinical studies included 366 patients with a diagnosis of arterial hypertension (n=107),
coronary heart disease (n= 104), lower extremity arterial disease (n= 100), and ischemic stroke
(n= 55). Patients were tested with the diagnostic method Lipoprint LDL System, which
quantifies atherogenic lipoproteins and identifies an atherogenic and a non-atherogenic
lipoprotein profile [29]. This was a fundamental methodological contribution of this new
analytical and diagnostic method.
Our study confirmed that more than 80% of tested patents with cardiovascular diseases have
an atherogenic lipoprotein profile, with a high level of strongly atherogenic small dense LDL.
The atherogenic lipoprotein profile was found to be the overwhelming lipoprotein profile in
tested cardiovascular diseases. Such a profile was found in arterial hypertension in 78.5%, in
coronary heart disease in 81.7%, in lower extremity arterial disease in 80%, and in patients who
survived an ischemic stroke in 85%. The average atherogenic lipoprotein profile in all these
tested diagnoses in the study was found to be of 81.3%.
This study also highlights the observation that, in the atherogenic lipoprotein profiles, in all
diagnoses, compared to the non-atherogenic profiles, the concentration of total cholesterol is
lower (n.s.) and the concentration of triglycerides is higher (even statistically significant; in
AH, CHD, LEAD, as well as in the control group, up to p<0.002). Hypertriglyceridemia
accompanied the hypercholesterolemia in all tested diagnoses, that is, in AH, CHD, LEAD,
and stroke). The concentration of triglycerides, compared to the control group, was signifi‐
cantly increased (p<0.0001) and proportionally even higher than cholesterol. From this result,
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it can be assumed that triglycerides/hypertriglyceridemia can play a much more important
role than was generally accepted, as until now the most important role in the pathogenesis of
vascular degenerative atherosclerotic injury was attributed to cholesterol and hypercholester‐
olemia. Our present results are in agreement with other authors, who have called attention to
hypertriglyceridemia as a risk factor for cardiovascular diseases [8,12,19, 36,58], as triglyceride-
rich lipoproteins can generate small dense LDL in high quantities [46].
The strong atherogenic lipoproteins – small dense LDL – have been found in the lipoprotein
profile of all diagnostic groups [25,52,55,56]. Their presence is decisive for an atherogenic
profile declaration. This is a rule that is valid not only for a hyperlipidemia, but also for a
normolipidemia.
In the case of normolipidemia (see the atherogenic lipoprotein profile in the control group), a
new phenomenon could be established – atherogenic normolipidemia [44] – as a risk factor for
the development of cardiovascular disease. A special form of normolipidemia can also be
atherogenic. This is new knowledge, and this new knowledge could help in the prevention
and treatment of cardiovascular disease.
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